ArticlePloS one2015
Diacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarction.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Amelioration of intestinal ischemia reperfusion injury by diacerein via regulation of inflammasome/caspase-1/IL-1β and Wnt/β-catenin pathways in juvenile rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study.Frontiers in pharmacology · 2024Article
- Diacerein ameliorates cholestasis-induced liver fibrosis in rat via modulating HMGB1/RAGE/NF-κB/JNK pathway and endoplasmic reticulum stress.Scientific reports · 2023Article
- Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: Therapeutic potential for liver fibrosis.Genes & diseases · 2023Review
- Interleukin-6 expression and its modulation by diacerein in a rat model of chronic stress induced cardiac dysfunction.Heliyon · 2021Article
- Dapsone Ameliorates Isoproterenol-Induced Myocardial InfarctionFrontiers in pharmacology · 2021Article
- Chrysophanol Protects Against Acute Heart Failure by Inhibiting JNK1/2 Pathway in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosis.Scientific reports · 2020Article
- Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-β1/ERK1/2 noncanonical pathway.Frontiers in pharmacology · 2020Article
- Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases.Frontiers in pharmacology · 2019Article
- Loss of miR-144 signaling interrupts extracellular matrix remodeling after myocardial infarction leading to worsened cardiac function.Scientific reports · 2018Article
- Chaihulonggumulitang Shows Psycho-cardiology Therapeutic Effects on Acute Myocardial Infarction by Enhancing Bone Marrow Mesenchymal Stem Cells Mobilization.Scientific reports · 2018Article
- Inhibition of inflammation using diacerein markedly improved renal function in endotoxemic acute kidney injured mice.Cellular & molecular biology letters · 2018Article
- Association of genetic variations in the Wnt signaling pathway genes with myocardial infarction susceptibility in Chinese Han population.Oncotarget · 2016Article
- Circulating microRNAs indicate cardioprotection by sevoflurane inhalation in patients undergoing off-pump coronary artery bypass surgery.Experimental and therapeutic medicine · 2016Article
- Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism.PloS one · 2016Article
- Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats.Journal of toxicology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe inflammatory response has been implicated in the pathogenesis of left ventricular (LV) remodeling after myocardial infarction (MI). An anthraquinone compound with anti-inflammatory properties, diacerein inhibits the synthesis and activity of pro-inflammatory cytokines, such as tumor necrosis factor and interleukins 1 and 6. The purpose of this study was to investigate the effects of diacerein on ventricular remodeling in vivo. METHODS AND
resultsLigation of the left anterior descending artery was used to induce MI in an experimental rat model. Rats were divided into two groups: a control group that received saline solution (n = 16) and a group that received diacerein (80 mg/kg) daily (n = 10). After 4 weeks, the LV volume, cellular signaling, caspase 3 activity, and nuclear factor kappa B (NF-κB) transcription were compared between the two groups. After 4 weeks, end-diastolic and end-systolic LV volumes were reduced in the treatment group compared to the control group (p < .01 and p < .01, respectively). Compared to control rats, diacerein-treated rats exhibited less fibrosis in the LV (14.65%± 7.27% vs. 22.57%± 8.94%; p < .01), lower levels of caspase-3 activity, and lower levels of NF-κB p65 transcription.
conclusionsTreatment with diacerein once a day for 4 weeks after MI improved ventricular remodeling by promoting lower end-systolic and end-diastolic LV volumes. Diacerein also reduced fibrosis in the LV. These effects might be associated with partial blockage of the NF-κB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.